Artesunate/pyronaridine - Medicines for Malaria Venture/Shin Poong Pharmaceutical
Alternative Names: M-PA01; PANDA; Pyramax; Pyronaridine-Artesunate - Medicines for Malaria Venture/Shin Poong Pharmaceutical; Pyronaridine/artesunate - Medicines for Malaria Venture/Shin Poong PharmaceuticalLatest Information Update: 26 Jun 2023
At a glance
- Originator Medicines for Malaria Venture; Shin Poong Pharmaceutical
- Class Antimalarials; Antivirals; Chlorinated hydrocarbons; Naphthyridines; Peroxides; Pyrrolidines; Sesquiterpenes; Small molecules
- Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malaria
- Phase III COVID 2019 infections
Most Recent Events
- 24 Mar 2023 Shin Poong Pharmaceutical completes a Phase-III clinical trials in COVID-2019 infections in United Kingdom, Colombia, Chile, Argentina, Poland, South Korea (PO) (NCT05084911)
- 20 Nov 2022 Shin Poong Pharmaceutical completes a Phase-II clinical trials in COVID-2019 infections in South Korea (PO) (NCT05633420)
- 16 Dec 2021 Medicines for Malaria Venture in collaboration with Richmond Pharmacology Limited and PharmaKinetic Ltd plans a phase I trial in healthy volunteers (Combination therapy) in the United Kingdom (NCT05160363)